 RESEARCH AND PRACTICE  Objectives. This study evaluated the effect of comorbidity at diagnosis on racial differences in survival among men with prostate cancer.
lished. Therefore, we performed a retrospective cohort study of the effect of comorbidity on survival outcomes in a biracial cohort of incident cancers diagnosed in the Chicago area. Our objective was to evaluate the prognostic significance of comorbidity at the time of diagnosis in relation to cause-specific mortality in both early-and advanced-stage prostate cancer and in Black and White men. This article focuses on the effect of comorbidity on racial differences in survival. We hypothesized that baseline differences in comorbidity would help explain racial variation in all-cause mortality beyond that caused by differences in age, stage at presentation, histological characteristics, and treatment patterns.
METHODS Cohort Selection
Our cohort consisted of all cases of adenocarcinoma of the prostate diagnosed among Black and White men at 4 academic medical centers in the Chicago area (2 private university medical centers and 2 Department of Veterans Affairs [VA] medical centers with university affiliations) between January 1, 1986 , and December 31, 1990. These hospi- tals were selected because a substantial proportion (approximately 40%) of the combined cohort consists of Blacks and, according to 1990 US census data, Blacks and Whites admitted to these hospitals form a socioeconomically diverse group. 14 We identified from the tumor registry at each hospital 1163 cases (613 university, 550 VA) of adenocarcinoma of the prostate (International Classification of Diseases, Ninth Revision, Clinical Modification code 187.0). 15 After obtaining appropriate institutional review board approvals at each of the participating hospitals, we attempted to locate the records of these patients. Of the 1163 patients originally identified, 1007 (87%) had medical records available for detailed review.
Racial Differences in Survival Among

Baseline Characteristics
Inpatient and outpatient medical records were abstracted on-site by 2 trained reviewers who had no knowledge of the hypotheses under study. The data abstracted from each record included demographics (name, race, date of birth, social security number, and per capita income by zip code), tumor characteristics (stage, tumor differentiation, and Gleason sum 16 ), processes of diagnosis and manageBlack men with prostate cancer have poorer disease-specific and overall survival rates than do their US White counterparts. 1 Blacks not only tend to present with more advanced disease but also experience a survival disadvantage within stages. 2 Attempts to elucidate the factors responsible for this disparity have focused on hypotheses ranging from genetic factors to health care system failure. [3] [4] [5] [6] [7] Some investigators have observed a narrowing of the Black-White survival gap with increasing age. 8, 9 Such a phenomenon could be explained, in part, by race-by-age-group differences in comorbidity. For example, in 1990 the mortality rate from ischemic heart disease among US men aged 45-64 years was higher among Blacks than among Whites (279 vs 237 per 100000 for Blacks and Whites, respectively). 10 However, among men aged 65 years and older, these mortality rate patterns were reversed (1375 vs 1584 per 100000 for Blacks and Whites, respectively). Hence, it may be that fewer Black men older than 65 years have died from ischemic heart disease than otherwise might have been the case, given that those with more severe disease were removed from the cohort through fatalities at younger ages. Therefore, an improved overall survival among Blacks diagnosed with prostate cancer at older ages could reflect, among other things, the influence of a reduced burden of comorbid conditions. Comorbidity at the time of diagnosis has been shown to predict both overall survival and cause-specific mortality among White men with localized prostate cancer. 11, 12 In fact, comorbidity has emerged as an important determinant of interindividual variation in prognosis, and the use of comorbidity to estimate the risks of death from other causes is recommended as a standard part of prostate cancer disease detection and management. 13 The role that initial levels of comorbidity play in determining intergroup variation in survival of prostate cancer patients is less well estab- 
Exclusions
We reviewed 1007 records and excluded 90 because the cancers were T1a lesions, which are believed to be clinically insignificant, and excluded 53 because of incomplete data or missing records, leaving 864 records (479 university, 385 VA) for analysis. Whereas Blacks accounted for 38.8% of the analytic cohort, 64% of the cases in Black men were diagnosed at one of the 2 VA hospitals. Of the records not found (n = 156), 42% were of Black cases.
Outcomes and Their Ascertainment
Follow-up ended at December 31, 2000, with death from prostate cancer and from other causes serving as the primary outcomes of interest. We used the tumor registries of the participating hospital as our primary source for vital status ascertainment, given that each hospital actively tracked vital status through regular letter and telephone contact with patients and their families. We also conducted multiple searches of the National Death Index and the Veterans Administration's Beneficiary Identification and Record Locator System through December 31, 2001, for deaths occurring on or before the end of the follow-up date but not recorded in the hospital tumor registry. The sensitivity of Beneficiary Identification and Record Locator System data is comparable to that of National Death Index data. 21 Other outcomes of interest included prostate cancer recurrence (date and location), cancer status (presence or absence) as of the date of last contact, and causes of death. Multiple-cause-ofdeath data were based on death certificate reviews performed by an independent physicianreviewer blinded to the study's hypotheses. Causes of death were coded according to the International Classification of Diseases.
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Statistical Methods
We 22 In our study, localized and regional-stage cases were combined, because they would both be candidates for aggressive primary therapy. The 3 histological subgroups used in our analyseswell, moderately, and poorly differentiated tumors-generally corresponded to Gleason sums of 2-4, 5-6, and 7-10, respectively. Unstaged cases were combined with distant cases, because their respective survival distributions were not significantly different (χ 2 1 = 0.30, P = .58). Charlson comorbidity scores were available for all but 3% of the cases. We used a multiple regression method to impute these values in which the available comorbidity score was regressed on age at diagnosis, race, hospital of origin, stage, tumor differentiation, and presence of other diseases or conditions (coronary artery disease, hypertension, and tobacco and alcohol usage). The primary outcomes for this study were (1) estimates of the effect of comorbidity at the time of prostate cancer diagnosis on overall survival and (2) cause-specific mortality given the patient's stage of prostate cancer and race after adjustment for the effects of age, tumor differentiation, and first-course treatment. A stratified Cox proportional hazards regression model was used to account for the baseline risk associated with the hospital in which the case originated. 23 The regression model included age, race (Black vs non-Black), Charlson comorbidity score, tumor differentiation (well, moderately, or poorly differentiated), stage (localized/ regional vs distant), and first-course treatment (surgery, radiation, diethylstilbestrol, castration, or observation). Potential interactions between comorbidity and stage and between comorbidity and race were evaluated by including a comorbidity-by-stage and a comorbidity-by-race term in the regression model. We used a bias-corrected bootstrap approach to compute 95% confidence intervals (95% CIs). 24 Briefly, we selected 2500 bootstrap samples and calculated the relative risk for each, generating an estimate of the empirical distribution of the parameter esti- RESEARCH AND PRACTICE  We considered a number of different regression models before reaching the final model. Time-dependent coefficients and Schoenfeld residuals were used to test the proportional hazards assumption in each of these models. 25 No violations of the proportional hazards assumptions were observed (P =.23 to .81). The statistical analyses were performed with the statistical package Stata Release 7.0. 26 
RESULTS
Baseline Characteristics
Although there were no significant racial differences in age and differentiation in our cohort, Blacks tended to present with distantstage disease more often than did their White counterparts (41.3% vs 25.1%, P <.001) and to experience a shorter interval between diagnosis and death (4.9 years vs 5.9 years, P <.001) and higher all-cause mortality (67.9% vs 53.1%, P <.001; Table 1 ). In addition, Blacks were twice as likely to have localized cancer initially managed with observation (12.1% vs 5.9%, P =.026), half as likely to have regional disease treated with radiation (28.3% vs 58.8%, P <.001), and 22% less likely to undergo surgical or medical castration for distant-stage disease (56.8% vs 72.9% for Black and Whites, respectively, P =.006).
Comorbidity Scores and Most Common Diagnoses
Initial comorbidity was greater among Blacks relative to Whites (mean Charlson score 2.0 for Blacks vs 1.6 for Whites, P = .001; Table 2 ). Further stratification by Charlson score revealed a trend toward overrepresentation of Blacks in each score group, with their proportion relative to Whites generally increasing with increasing score (0.67, 1.08, 1.33, 1.17, and 1.31 for scores of 0, 1, 2, 3 and ≥ 4, respectively). Diabetes mellitus was the most common condition present at the time of prostate cancer diagnosis in our cohort. The disease was one third more prevalent among Blacks (21.7% and 16.0% for Blacks and Whites, respectively, P = .078), with complications (retinopathy, nephropathy, neuropathy) significantly more common among Blacks than among Whites (4.9% and 2.8%, respectively, P = .002). Renal disease, defined as serum creatinine ≥ 3 mg% or a history of renal transplantation, was also significantly more common among Blacks relative to Whites (8.6% vs 5.0%, P = .039), as was cerebrovascular disease with hemiplegia (7.0% vs 4.1%, P < .001). During the followup period, 507 (58.7%) men died-215 from prostate cancer and 292 from other causes. Survival varied by race for localized/regionalstage cases (χ 2 = 5.59, P < .0181) but not for distant-stage cases (χ 2 = 2.10, P < .147).
Relative Risks of Death by Cause
After adjustment for age, stage, differentiation, treatment, and initial comorbidity, Blacks had significantly greater risks of death from prostate cancer (relative risk Figure 1 shows the change in relative risk for death from prostate cancer, other causes, and any cause for Blacks versus Whites by On oral hypoglycemics or insulin. 
Impact of Initial Comorbidity on Racial Differences in Survival
Summary
Comorbidity at the time of diagnosis in our cohort was significantly higher among Black men than among White men. After we controlled for age, tumor characteristics, treatment, and initial comorbidity, Blacks had significantly greater (1.5-to 2-fold) risks of death from prostate cancer and from other causes. Comorbidity as measured with the Charlson index was an independent predictor of death from causes other than prostate cancer (but not of death caused by prostate cancer). After stratification by level of comorbidity at time of diagnosis, significant racial differences in survival eventually disappeared as initial comorbidity increased.
DISCUSSION
Among Black men diagnosed with prostate cancer, the absence of a significant preexisting medical diagnosis was associated with a higher risk of excess mortality from any cause, including prostate cancer. Modification of the Black-White survival gap by comorbidity in- dicates an interaction between race and comorbidity, and this is supported statistically in our model (coefficient for the race × comorbidity interaction term = -0.132, P = .001).
More aggressive tumors among Blacks may render comorbidities less prognostically important because of greater competition from prostate cancer as a cause of death. However, Figure 1 suggests other, more likely pathways to racial disparities in prostate cancer outcomes. Race may act as a surrogate for social and cultural forces that influence the probability, content, and quality of relationships between health care systems and providers. Indeed, the literature is overflowing with evidence of disparities in the level and quality of care received by US minority populations relative to White populations. 27 It is possible that for Black men, the absence of other known major diagnoses around the time their prostate cancer is detected may be attributable to underdiagnosis of those conditions or to underdiagnosis and poorer control of risk factors. Because we did not collect more data pertinent to these factors, we cannot directly test this hypothesis as it relates to racial differences in prostate cancer prognosis in our cohort. However, diagnosis of prostate cancer at an early stage was associated with a significantly lower risk of death from causes other than prostate cancer. To our knowledge, there is no biological reason for this finding. Furthermore, we did not observe an interaction between stage and comorbidity in our cohort (P value = .852). Early-stage diagnosis may correlate with a prior history of care or pattern of early diagnosis and with secondary prevention that favorably affects patient longevity. We also observed a trend of decreasing excess all-cause and cause-specific mortality among Blacks as baseline comorbidity scores increased. In fact, this inverse association seemed to follow a dose-response relation. However, a "crossover" effect characterized by progressively better survival among Blacks relative to Whites as comorbidity increases seems unlikely.
Limitations
Because our cohort was limited to the Chicago metropolitan area, our results may not be generalizable to other settings. Also, our case patients were diagnosed between 1986 and 1990. Prostate-specific antigen testing was just being introduced during this period, and its use was not yet widespread. Therefore, more men had advanced-stage cancer at diagnosis, especially early on, and their care may have differed from current management in clinically important ways. As mentioned, 26% of the patients originally identified could not be included in the analysis. However, it seems unlikely that significant biases were introduced as a result of the exclusions, for several reasons. First, the excluded and analyzed groups each contained a comparable proportion of Blacks (42.0% vs 38.8% for excluded and analyzed cases, respectively). Second, after exclusion of the 90 incidental prostatic adenocarcinomas from the 1163 cases originally identified, 1073 men had lesions deemed clinically significant. Therefore, 80.5% of the clinically significant carcinomas were included in the analysis. Nevertheless, sample sizes for groups with the highest scores were relatively small. Larger sample sizes would have improved precision in estimating the effect of comorbidity on the Black-White survival gap.
CONCLUSIONS
The causes of prostate cancer may continue to elude investigators for some time. Until these causes are determined, a sustained focus on equalizing outcomes of the disease among groups-to the extent possible given our limited understanding of the causative exposures-will continue to be necessary. 28 We evaluated the hypothesis that comorbidity at the time of diagnosis would help explain some of the racial disparity in all-cause mortality beyond that explained by differences in demographic, tumor, and treatment characteristics. Comorbidity did account for some of the increased mortality from other causes among Blacks relative to Whites. However, our data further indicated that the absence of a significant preexisting medical diagnosis was in itself a risk factor for excess mortality among Black men diagnosed with prostate cancer. This association probably reflects the action of cultural and social forces (rather than a racial effect per se) that lead to underdetection or delayed detection of prognostically important comorbidities or risk factors thereof.
